Oxalate-Degrading Enzyme Recombined Lactic Acid Bacteria Strains Reduce Hyperoxaluria

Objective To develop recombinant lactic acid bacteria (LAB) strains that express oxalate-degrading enzymes through biotechnology-based approach for the treatment of hyperoxaluria by oral administration. Material and Methods The coding gene of oxalate decarboxylase (ODC) and oxalate oxidase (OxO) was transformed into Lactococcus lactis MG1363. The oxalate degradation ability in vitro was evaluated in media with high concentration of oxalate. Hyperoxaluria rat models through high oxalate diet were given recombinant LAB through oral administration. Twenty-four-hour urinary oxalate was measured, and kidney stone formation was investigated. Results LAB recombined with the coding gene of ODC could effectively decrease the amount of oxalate in the media and in the urine of rats. Moreover, the formation of calcium oxalate crystals in kidneys was also inhibited. The acid-induced promoter p170 significantly enhanced the reduction of hyperoxaluria. However, recombinant LAB expressing heterologous OxO showed less efficiency in oxalate degradation even in the presence of p170. Conclusion LAB expressing ODC is more efficient in degradation of oxalate in vitro and in vivo than that expressing OxO. This present study provided novel recombinant probiotic strains as a potential treatment tool against oxalosis.